S&P 500   3,954.74 (+0.15%)
DOW   32,132.48 (+0.08%)
QQQ   309.16 (-0.19%)
AAPL   159.28 (+0.22%)
MSFT   278.11 (+0.16%)
META   205.12 (+0.41%)
GOOGL   104.76 (-0.80%)
AMZN   97.61 (-1.11%)
TSLA   189.46 (-1.44%)
NVDA   264.91 (-2.57%)
NIO   8.95 (-3.45%)
BABA   86.34 (-0.21%)
AMD   97.48 (-2.79%)
T   18.53 (+0.38%)
F   11.46 (+0.35%)
MU   60.69 (-1.06%)
CGC   1.90 (-0.29%)
GE   90.85 (-0.81%)
DIS   93.78 (-2.14%)
AMC   4.47 (+0.00%)
PFE   40.31 (+0.32%)
PYPL   73.50 (+1.30%)
NFLX   325.93 (+1.74%)
S&P 500   3,954.74 (+0.15%)
DOW   32,132.48 (+0.08%)
QQQ   309.16 (-0.19%)
AAPL   159.28 (+0.22%)
MSFT   278.11 (+0.16%)
META   205.12 (+0.41%)
GOOGL   104.76 (-0.80%)
AMZN   97.61 (-1.11%)
TSLA   189.46 (-1.44%)
NVDA   264.91 (-2.57%)
NIO   8.95 (-3.45%)
BABA   86.34 (-0.21%)
AMD   97.48 (-2.79%)
T   18.53 (+0.38%)
F   11.46 (+0.35%)
MU   60.69 (-1.06%)
CGC   1.90 (-0.29%)
GE   90.85 (-0.81%)
DIS   93.78 (-2.14%)
AMC   4.47 (+0.00%)
PFE   40.31 (+0.32%)
PYPL   73.50 (+1.30%)
NFLX   325.93 (+1.74%)
S&P 500   3,954.74 (+0.15%)
DOW   32,132.48 (+0.08%)
QQQ   309.16 (-0.19%)
AAPL   159.28 (+0.22%)
MSFT   278.11 (+0.16%)
META   205.12 (+0.41%)
GOOGL   104.76 (-0.80%)
AMZN   97.61 (-1.11%)
TSLA   189.46 (-1.44%)
NVDA   264.91 (-2.57%)
NIO   8.95 (-3.45%)
BABA   86.34 (-0.21%)
AMD   97.48 (-2.79%)
T   18.53 (+0.38%)
F   11.46 (+0.35%)
MU   60.69 (-1.06%)
CGC   1.90 (-0.29%)
GE   90.85 (-0.81%)
DIS   93.78 (-2.14%)
AMC   4.47 (+0.00%)
PFE   40.31 (+0.32%)
PYPL   73.50 (+1.30%)
NFLX   325.93 (+1.74%)
S&P 500   3,954.74 (+0.15%)
DOW   32,132.48 (+0.08%)
QQQ   309.16 (-0.19%)
AAPL   159.28 (+0.22%)
MSFT   278.11 (+0.16%)
META   205.12 (+0.41%)
GOOGL   104.76 (-0.80%)
AMZN   97.61 (-1.11%)
TSLA   189.46 (-1.44%)
NVDA   264.91 (-2.57%)
NIO   8.95 (-3.45%)
BABA   86.34 (-0.21%)
AMD   97.48 (-2.79%)
T   18.53 (+0.38%)
F   11.46 (+0.35%)
MU   60.69 (-1.06%)
CGC   1.90 (-0.29%)
GE   90.85 (-0.81%)
DIS   93.78 (-2.14%)
AMC   4.47 (+0.00%)
PFE   40.31 (+0.32%)
PYPL   73.50 (+1.30%)
NFLX   325.93 (+1.74%)
NASDAQ:TGTX

TG Therapeutics - TGTX News Today

$14.47
-0.44 (-2.95%)
(As of 03/24/2023 02:15 PM ET)
Add
Compare
Today's Range
$14.23
▼
$14.93
50-Day Range
$11.82
▼
$19.34
52-Week Range
$3.48
▼
$19.59
Volume
777,497 shs
Average Volume
4.54 million shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.


TGTX Media Mentions By Week

TGTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TGTX
News Sentiment
▼
0.43

0.36
▲
Average
Medical
News Sentiment

TGTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TGTX Articles
This Week
▼
3

3
▲
TGTX Articles
Average Week

SourceHeadline
marketbeat.com logoHennion & Walsh Asset Management Inc. Sells 68,140 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
marketbeat.com - March 22 at 5:45 AM
bizjournals.com logoPublic company quietly moves executive offices to Morrisville
bizjournals.com - March 24 at 10:28 AM
MarketBeat logoTG Therapeutics (NASDAQ:TGTX) Shares Gap Down to $14.92
americanbankingnews.com - March 24 at 5:34 AM
bizjournals.com logoPublic company moves executive offices to Morrisville
bizjournals.com - March 23 at 8:20 AM
MarketBeat logoTG Therapeutics (NASDAQ:TGTX) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - March 17 at 6:54 AM
finance.yahoo.com logoTG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know
finance.yahoo.com - March 16 at 12:17 AM
MarketBeat logoAnalysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Target Price at $18.00
americanbankingnews.com - March 14 at 2:54 AM
msn.com logoTG Therapeutics’ price for multiple sclerosis therapy is not low enough - ICER
msn.com - March 9 at 5:39 PM
finance.yahoo.com logoTG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Call Transcript
finance.yahoo.com - March 9 at 5:39 PM
finance.yahoo.com logoTG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
finance.yahoo.com - March 3 at 4:27 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - February 28 at 5:57 PM
seekingalpha.com logoTG Therapeutics' Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market
seekingalpha.com - February 25 at 4:48 PM
finance.yahoo.com logoTG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
finance.yahoo.com - February 24 at 7:39 AM
finance.yahoo.com logoTG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
finance.yahoo.com - February 24 at 7:39 AM
finance.yahoo.com logoTG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
finance.yahoo.com - February 24 at 7:39 AM
finance.yahoo.com logoTG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
finance.yahoo.com - February 24 at 7:39 AM
finance.yahoo.com logoBiotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment
finance.yahoo.com - February 15 at 7:35 PM
finance.yahoo.com logoTG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
finance.yahoo.com - February 14 at 9:16 AM
msn.com logoHere's How Much $100 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today
msn.com - February 7 at 8:57 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
finance.yahoo.com - February 7 at 8:57 PM
msn.com logoTG Therapeutics up as Cantor sees a “strong launch” for multiple sclerosis therapy
msn.com - February 7 at 10:54 AM
seekingalpha.com logoTG Therapeutics: Strategy After Briumvi Launch
seekingalpha.com - February 1 at 1:30 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
finance.yahoo.com - January 30 at 11:46 PM
msn.com logoTG Therapeutics launches newly approved multiple sclerosis therapy
msn.com - January 26 at 4:00 PM
finance.yahoo.com logoTG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
finance.yahoo.com - January 26 at 10:19 AM
msn.com logoTG Therapeutics stock adds over 10% to reach one-year high
msn.com - January 24 at 5:43 PM
msn.com logoThe Latest Analyst Ratings for TG Therapeutics
msn.com - January 24 at 5:43 PM
wsj.com logoSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TG Therapeutics, Inc.
wsj.com - January 24 at 2:18 AM
msn.com logoHere's How Much $1000 Invested In TG Therapeutics 10 Years Ago Would Be Worth Today
msn.com - January 19 at 2:46 PM
seekingalpha.com logoTGTX TG Therapeutics, Inc.
seekingalpha.com - January 18 at 3:24 PM
finance.yahoo.com logoTG Therapeutics' (NASDAQ:TGTX) investors will be pleased with their 26% return over the last five years
finance.yahoo.com - January 18 at 10:23 AM
seekingalpha.com logoTG Therapeutics adds 10% to extend gains after insider purchase
seekingalpha.com - January 13 at 11:38 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
finance.yahoo.com - January 12 at 7:46 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
finance.yahoo.com - January 12 at 9:46 AM
msn.com logoStocks making the biggest moves midday: TG Therapeutics, Micron Technology, ChargePoint and more
msn.com - December 31 at 8:37 AM
markets.businessinsider.com logoAnalyst Ratings for TG Therapeutics
markets.businessinsider.com - December 30 at 2:01 PM
seekingalpha.com logoHot Stocks: EV rally; CB sets 52-week high; CALM drops on earnings; TGTX extends advance
seekingalpha.com - December 29 at 11:39 PM
markets.businessinsider.com logoB.Riley Financial Keeps Their Buy Rating on TG Therapeutics (TGTX)
markets.businessinsider.com - December 29 at 6:33 PM
finance.yahoo.com logoNow That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets
finance.yahoo.com - December 29 at 6:33 PM
marketwatch.com logoTG Therapeutics Shares Extend Gains Following FDA Approval of Briumvi
marketwatch.com - December 29 at 1:33 PM
benzinga.com logoWhat's Going On With TG Therapeutics Shares
benzinga.com - December 29 at 1:33 PM
benzinga.com logoHC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know
benzinga.com - December 29 at 1:33 PM
seekingalpha.com logoTG Therapeutics surges as focus turns to launch of new multiple sclerosis therapy
seekingalpha.com - December 29 at 1:33 PM
msn.com logoB of A Securities Maintains Underperform Rating for TG Therapeutics: Here's What You Need To Know
msn.com - December 29 at 1:33 PM
finance.yahoo.com logoTG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
finance.yahoo.com - December 29 at 1:33 PM
markets.businessinsider.com logoH.C. Wainwright Keeps Their Buy Rating on TG Therapeutics (TGTX)
markets.businessinsider.com - December 29 at 8:32 AM
msn.com logoU.S. FDA approves TG Therapeutics' multiple sclerosis drug; shares surge
msn.com - December 29 at 12:11 AM
marketwatch.com logoTG Therapeutics Up 29% on FDA Approval of MS Drug Briumvi
marketwatch.com - December 28 at 7:10 PM
markets.businessinsider.com logoHere's Why TG Therapeutics (TGTX) Shares Are Skyrocketing
markets.businessinsider.com - December 28 at 7:10 PM
finance.yahoo.com logoPfizer Makes Progress, but This Biotech Was Wednesday's Big Winner
finance.yahoo.com - December 28 at 7:10 PM
marketwatch.com logoFDA Approves TG Therapeutics Inc.'s MS Drug Briumvi
marketwatch.com - December 28 at 2:06 PM
Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:TGTX) was last updated on 3/24/2023 by MarketBeat.com Staff